Forum

@jennifer-carroll

The updated Health Canada Policy Document "Guidance on distinction between advertising and other activities for health products" no longer includes the above 4 criteria for International Conferences held in Canada, but instead includes the following two elements that may render these events promotional:
"• display of a drug product prior to market authorization in Canada is not prominently identified as not being
authorized for sale in Canada
• there are actions intended to target the Canadian general public directly or indirectly"

I was hoping you could help provide some clarity as to how we can ensure the materials we are presenting at an International conference held in Canada are not subject to the Canadian advertising regulations (and thus falls outside of PAAB's scope). Do we still ensure the same 4 criteria are ALL followed? Or are there any additional considerations/changes based on the updated guidance document?

Thanks in advance!

@jennifer-carroll

I had a follow-up question regarding the 2 requirements needed to support a “#1 dispensed” claim:

What is the minimum amount of time that a competitor product in the same category needs to be available in Canada (i.e., NOC received) before a “#1 dispensed” claim would be considered acceptable? (Assuming all other requirements as per the Guidance document were met).

Would it be acceptable to make such a claim if all other product(s) in the same category received NOC less than 12 months ago?

Thank you!